- Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
- Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
- Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
- Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
- Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
- Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
- Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
- Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
More ▼
Key statistics
On Thursday, Beam Therapeutics Inc (BEAM:NSQ) closed at 24.01, 41.65% above the 52 week low of 16.95 set on Oct 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 24.91 |
---|---|
High | 24.91 |
Low | 23.57 |
Bid | 24.00 |
Offer | 25.90 |
Previous close | 24.88 |
Average volume | 1.10m |
---|---|
Shares outstanding | 82.31m |
Free float | 81.06m |
P/E (TTM) | -- |
Market cap | 2.05bn USD |
EPS (TTM) | -1.74 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼